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Abstract
Background: Genetic modification is a prerequisite to realizing the full potential of human embryonic stem cells (hESCs) in
human genetic research and regenerative medicine. Unfortunately, the random integration methods that have been the
primary techniques used keep creating problems, and the primary alternative method, gene targeting, has been effective in
manipulating mouse embryonic stem cells (mESCs) but poorly in hESCs.
Methodology/Principal Findings: Human ribosomal DNA (rDNA) repeats are clustered on the short arm of acrocentric
chromosomes. They consist of approximately 400 copies of the 45S pre-RNA (rRNA) gene per haploid. In the present study,
we targeted a physiological gene, human coagulation factor IX, into the rDNA locus of hESCs via homologous
recombination. The relative gene targeting efficiency (.50%) and homologous recombination frequency (.10
25) were
more than 10-fold higher than those of loci targeted in previous reports. Meanwhile, the targeted clones retained both a
normal karyotype and the main characteristics of ES cells. The transgene was found to be stably and ectopically expressed in
targeted hESCs.
Conclusion/Significance: This is the first targeting of a human physiological gene at a defined locus on the hESC genome.
Our findings indicate that the rDNA locus may serve as an ideal harbor for transgenes in hESCs.
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Introduction
Over the past thirty years, the combined use of murine
embryonic stem cells (mESCs) and gene targeting, which allows
researchers to study gene function in vivo, has revolutionized
developmental research [1]. Parallel to mESCs, human embryonic
stem cells (hESCs) can also proliferate indefinitely and differentiate
into multiple lineages both in vitro and in vivo [2]. More
importantly, because they have a human genetic background,
they may be powerful tools in the study of human genes and in
regenerative medicine. Unfortunately, the gene targeting strategy
that is most widely used to manipulate mESCs has worked poorly
in hESCs due to their resistance to non-viral transfection and
sensitivity to single-cell cloning. So far, only a dozen sites have
been successfully targeted in hESCs [3–15]. Random transgene
integration is the method of genetic modification most commonly
used with hESCs; but the uncertainty of the integration site leads
to other problems. A transgene may become silenced if it is
integrated into a heterochromatin area, or it may disrupt or
activate endogenous genes, leading to apoptosis or otherwise
changing the cell’s fate. In addition, because it is thought that
random integration is mediated by non-homologous end joining
(NHEJ), an imprecise DNA-repair mechanism, integration may be
incomplete and plasmid debris may end up integrated into the
genome [16,17]. These problems may be solved if the transgene is
targeted to an appropriate site where it can be expressed without
any serious functional consequences [18].
Human 45S ribosomal DNA (rDNA) is clustered on the short
arm of all five acrocentric chromosomes (chromosomes 13, 14,
15, 21, and 22). It consists of approximate 400 copies of the
45S pre-RNA (rRNA) gene per haploid [19]. The rRNA gene is
transcriptionally active, producing approximately 80% of the
total RNA in rapidly dividing cells. Loss or gain of the short
arm of acrocentric chromosomes is common in humans and
does not usually have any phenotypic effects and can be
inherited stably. Balanced translocations between the short arm
of an acrocentric chromosome and the other chromosomes are
also observed without apparent phenotypic effect. For this
reason, we presumed that transgenes targeted into the rDNA
locus would be transcriptionally active without any unexpected
effects. The rDNA locus is a candidate harbor favorable for
effective and safe transgene cell manipulations. A recent report
revealed that the rDNA cluster exhibited strikingly variable
lengths between and within human individuals and showed high
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mitosis [20]. This indicates that a high rate of gene targeting
may be achieved. The transgene targeted into the rDNA locus
is expected to work in hESCs.
In this report, we targeted human coagulation factor IX, a
physiological gene, into the rDNA locus via homologous
recombination and found the process to be highly efficient. We
here demonstrated that the integrated clones retained the main
characteristics of ES cells. After long-term culture, the targeted
cells retained a normal karyotype and expressed the transgene
stably. Our findings provide a new strategy for manipulating
hESCs in both basic and applied research.
Results
We constructed an rDNA-targeting plasmid, pHrnF9, which
introduced a promoterless neomycin resistance (neo) cassette and
an EF1-a driven human coagulation factor IX (F9) open reading
frame into the 45S pre-RNA gene. The two cassettes were flanked
by a 59 long homologous arm (4.5 kb) and a 39 short homologous
arm (1.1 kb). The first cassette contained an encephalomyocarditis
virus internal ribosomal entry site (EMCV-IRES), which enabled
resistant gene expression under the control of endogenous RNA
polymerase I (Pol I) promoter upstream after homologous
recombination (Figure 1).
Prior to targeting hESCs, we tested the new plasmid construct
in HT1080 cells via electroporation. We did two gene targeting
experiments on HT1080 cells (Table S1). In one of the
experiments, three million HT1080 cells were exposed to a single
2000 V, 50 mF pulse with 20 mg linearized pHrnF9 at room
temperature using the BioRad Gene Pulser II (0.4 cm gap cuvette,
BioRad, Hercules, CA, U.S.). Up to 400 mg/ml of G418 (Sigma,
St Louis, MO, U.S.) was added 72 hours after electroporation.
Finally, 997 resistant clones were obtained (Table S1). Out of the
39 clones screened by PCR, 12 were identified as homologous
recombinants. This indicated a relative targeting efficiency of 31%
and an absolute targeting frequency of 0.01%. These values are
higher than those of any previous gene targeting experiment
performed on HT1080 cells. The targeted clones secreted F9
protein stably (Table S2).
For gene targeting of hESCs, we nucleofected trypsinized H9
hESCs, using 10 mM rho-associated kinase (ROCK) inhibitor Y-
27632 two hours before and during the 24 hours immediately after
nucleofection to improve single-cell survival. This method yielded
sufficiently high transfection efficiency (Figure 2a). G418 selection
was initiated 48–72 hours after transfection, starting at low drug
concentrations and slowly building up to 50 mg/ml. Because H9
cells are highly sensitive to G418, the initial drug concentration of
25 mg/ml was sufficient to kill untransfected cells. Drug-resistant
clones were picked and expanded for genotyping two weeks after
nucleofection. In a typical experiment, 3.2610
6 cells were
nucleofected with 5 mg linearized pHrnF9, and 57 drug-resistant
clones were obtained. Of the 22 clones analyzed, 14 targeted
clones were identified by PCR (Figure 2d) and Southern blot
analysis (Figures 2f and 2g). Relative targeting efficiency was 64%
(14/22) and the absolute homologous recombination frequency
was 1.13610
25. Both of these values are higher than those
reported in previous studies other than studies of artificial zinc
finger nucleases (ZFNs). Generally, dozens of clones were obtained
for each case of single nucleofection followed by two weeks of
selection. In a series of experiments, similar results were obtained
regularly (Table 1).
Following successful gene targeting of hESCs, we analyzed G-
banded chromosomes on nine targeted clones after genotyping,
and all showed normal karyotypes (Figure 2e). To confirm that the
targeted clones retained hESC characteristics after gene targeting,
we examined hESC marker expression. Immunocytochemistry
and alkali phosphatase (AP) staining revealed that the targeted
hESCs lines expressed stage-specific embryonic antigen (SSEA)-3
(Figure 3d), SSEA-4 (Figure 3e), tumor-related antigen (TRA)-1-
60 (Figure 3f), TRA-1-81 (Figure 3g), OCT 3/4 (Figure 3h), and
AP (Figure 3b). SSEA-1 was not expressed in undifferentiated cells
(Figure 3c). To determine the differentiation potential of the
targeted clones, we cultured the cells in suspension to form
embryoid bodies (EBs). After 7 days, the EBs were transferred to
gelatin-coated plates and cultured for another 7 days. Immuno-
Figure 1. Schematic representation of the rDNA unit, targeting vector, and targeted allele after homologous recombination. White
boxes represent the left (GenBank U13369: 937–5467) and right (GenBank U13369: 5468–6523) homologous arms. The neo cassette consisted of an
IRES element from the encephalomyocarditis virus, the coding region of the neo gene (NEO), and SV40 polyA signal (SpA). Neo lacks a promoter.
Expression is activated by the promoter of the rRNA gene after homologous recombination. Knock-in of neo open reading frame (NEO ORF) to the
rDNA unit caused an addition of PvuII site resulting in fragments of 7.1 kb and 10.3 kb after digestion. The F9 gene is driven by an EF1-apromoter.
Primer 1 (P1) and primer 2 (P2) bind to the bovine growth hormone polyA (BH pA) and the 5.8S RNA coding sequence beyond the homologous
sequence respectively, the PCR product will be 1.4 k after homologous recombination.
doi:10.1371/journal.pone.0037071.g001
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positive ectoderm (Figure 4b), a-fetoprotein (AFP)-positive endo-
derm (Figure 4a), and mesoderm positive for smooth muscle actin
(SMA) (Figure 4d). Upon directed differentiation, beating clumps
emerged (Figure 4c).These consisted of cadiocytes expressing
myosin light chain-2a (Figure 4e) and cardiac troponin I (Figure 4f).
To evaluate pluripotency in vivo, we injected the targeted cells
subcutaneously into immuno-compromised mice. Two months
later, the targeted cells generated various complex teratomas
comprising structures and tissues derived from the three embry-
onic germ layers, including gallbladder (endoderm) (Figure 5a),
colon (endoderm) (Figure 5b), respiratory epithelium (endoderm)
(Figure 5c), cartilage (mesoderm) (Figure 5d), striated muscle
(mesoderm) (Figure 5e), bone (mesoderm), and squamous epithe-
lium (ectoderm) (Figure 5f). Our data indicate that the rDNA-
targeted clones retained their ES characteristics.
To determine whether targeted transgene could be expressed at
the rDNA locus, reverse transcription PCR (RT-PCR) analysis
was carried out, revealing that wild-type H9 did not express
endogenous F9 and that the targeted clones did, even after 40
passages of contiguous culture (Figure 6a). Quantitative analysis
using enzyme linked immunosorbent assay (ELISA) showed that
Figure 2. Gene targeting of the rDNA locus in hESCs. (a) For hESC transfection, the efficiency was determined by transient nucleofection of H9
single cells by pmaxGFP. (b) Phase-contrast image of a resistant clone just before picking up. (c) After two weeks of drug selection, a portion of
resistant clones were picked up and the remaining clones were fixed and stained with Giemsa stain. Clones with diameters of $2 millimeters were
considered resistant. (d) PCR result using P1 and P2, and DNA sequencing of the PCR product. (e) The targeted clones showed a normal karyotype
(46, XX). (f–g) Southern blot analysis showed a 7.1 kb band for targeted clones using a 59 probe. When using a 39 probe corresponding to the second
exon of F9 gene, both a wild type 4.3 kb fragment and an integrated 10.3 kb fragment will be detected. M, marker. Scale bar =200 mm (a–b).
doi:10.1371/journal.pone.0037071.g002
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(Figure 6c), indicating the site-specifically integrated transgene
could be expressed in the targeted clones. It also showed that the
synthesized protein could be secreted into the supernatant.
Western blot analysis showed that the F9 protein could be
detected in both the cell lysate and concentrated supernatant
(Figure 6b and Figure S1). The different levels of transgene
expression observed among different targeted clones may have
been caused by the different targeted rDNA copies, which had
different transcriptional levels.
Discussion
In recent years, hESCs have been studied eagerly by thousands
of laboratories, but results have been disappointing because of
their low rate of transgenesis and homologous recombination
relative to mESCs. One of main characteristics of hESCs is the
maintenance of normal karyotypes after long-term culture. To
achieve this, they must maintain some kind of self-repairing
mechanism (such as homologous recombination) through hun-
dreds of mitotic divisions. For this reason, we think the intrinsic
frequency of homologous recombination may not be as low as
reported and the real barrier to hESC gene targeting is their
resistance to clonal expansion. This problem can be solved by
using of neurotrophin cocktail or ROCK inhibitor [21,22]. For
instance, once treated with Y27632, the survival rate of single
hESCs can be improved by more than two orders of magnitude
without sacrificing any ES properties [22]. By this means, we
achieved homologous recombination rate of more than 10
25 in
hESCs. In other studies, the difficulty of gene targeting has differed
from site to site [11]. The addition of Y27632 can only improve
clonal expansion, which directly results in increased numbers of
drug-resistant clones; but this does not, in theory, markedly alter
the ratio of homologous recombinants to non-homologous
recombinants. Normally the targeting efficiency of both mESCs
and hESCs is about 1%, but in our experiments, it was more than
50%. The gene-trap strategy that we used can partially explain
this, especially considering that this strategy has been reported to
be more effective than positive-negative selection [3,23]. However,
the main reason would seem to be the relatively high intrinsic
activity of homologous recombination at the rDNA locus.
Although there are about 400 copies of rDNA repeats per
haploid, it is, to our knowledge, uncertain whether the high
frequency of homologous recombination is due to the copy
number of target sites. A previous study proved that targeting does
not depend on the number of targets in mammalian cells [24].
However, recent study using ZFNs did obtain higher rate of gene
targeting in cells with two target sites than in cells with only one
[25].
ZFNs have been widely used to achieve efficient homologous
recombination of gene targeting vectors with various endogenous
loci in cultured and primary mammalian cells [26], even those
with very short homologous arms [27]. The customized artificial
nucleases can introduce DNA double strand breaks at target sites
and then stimulate the cell’s endogenous homologous recombina-
tion machinery. In this system, a donor DNA can replace any lost
portion of its corresponding chromosomal segment at high
efficiency. In 2009, two research groups successfully performed
gene targeting in hESCs using ZFNs. Hockemeyer et al. obtained
40 homologous recombinants among 42 resistant clones (relative
targeting efficiency 94%) using their most efficient ZFN pair
[28].An absolute targeting frequency of 0.14–0.24% was achieved
by Zou et al. [10]. ZFNs are usually superior when used to generate
a mixed population of targeted and untargeted cells without drug
selection. However, the use of ZFNs can be compromised by their
Table 1. Summary of the 4 experiments of gene targeting in
H9 cells.
Exp. N C S T R ATF RTE
1 1.8 32 23 13 10 9.9 56%
2 1.9 45 21 10 11 11.6 48%
3 3.2 57 22 14 8 11.3 64%
4 2.8 40 22 15 7 9.8 68%
Total 9.7 174 88 52 36 10.6 59%
Abbreviation: Exp., experiments were performed. N, Number of cells
nucleofected (610
6). C, total number of resistant clones obtained from each
experiment. S, number of clones screened. T, number of clones screened as
targeted recombinants. R, number of clones screened as random integrants.
ATF, absolute targeting frequency (610
26) = TC/NS. RTE, relative targeting
efficiency=T/S.
doi:10.1371/journal.pone.0037071.t001
Figure 3. Characterization of targeted clones. (a) Phase-contrast image of a targeted clone. (b) Alkali phosphatase staining of targeted clones.
(c–h) Immunocytochemical analysis of targeted clones with SSEA-1, SSEA-3, SSEA-4, Tra-1-60, Tra-1-81, and Oct4 antibody. Scale bar =200 mm for
micrographs.
doi:10.1371/journal.pone.0037071.g003
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In gene targeting of hESCs with the purpose of generating site-
specific edited recombinants, our strategy described here is more
effective and safer than the ZFNs method.
Human ROSA26 and ENVY loci are transcriptionally active and
considered to be candidate sites for targeted transgene integration
[5,29]. But it is uncertain whether the cells will exhibit functional
consequences when one of the two copies is disrupted. Another
hESC line for gene targeting has been reported. In this line, a
LoxP-docking site was introduced in to the HPRT locus [12]. This
cell line can be used for targeting exogenous sequences using the
Cre-Lox system. Because the first round of targeting is favorable to
an active X chromosome, disruption of the HPRT locus may lead
to a Lesch-Nyhan phenotype. In contrast, the human rRNA
cluster consists of hundreds copies of tandemly repeated rDNA
units. Variations in rDNA copy number are common among
healthy individuals and balanced chromosomal translocation
involving the rRNA cluster occurs without any apparent
phenotypic effect. These properties indicate that the rDNA locus
may hold a high intrinsic homologous recombination activity and
facilitate effective transgene expression. In the present study, the
rDNA locus was targeted with high efficiency, no undesired effect
was detected, and the transgene was expressed stably in the
integrated clones.
It has been reported that RNA polymerase II (Pol II)-
transcribed genes can be silenced at the rDNA locus in yeast
cells, especially under an active Pol I promoter [30,31]. In the
Figure 4. In vitro differentiation of targeted clones. Immunostaining images show cells derived from all three germ layers, including AFP
(endoderm), Tuj1 (ectodermal), and SMA (mesodermal) positive cells. Upon directed differentiation, cell clumps started beating rhythmically, and the
expression of Mlc-2a and cTn I revealed that the differentiation into cardiomyocytes in these cells had been completed. Scale bar =200 mm (a, c).
doi:10.1371/journal.pone.0037071.g004
Figure 5. Teratoma formation in immunodeficiency mice by
targeted cells. H&E staining of teratomas was performed. Derivatives
of all three germ layers were observed in the endoderm: (a) gallbladder,
(b) intestinal-like epithelium, and (c) respiratory epithelium; in the
mesoderm, (d) cartilage and (e) muscle; and in the ectoderm, (f)
squamous epithelium. Bar =200 mm.
doi:10.1371/journal.pone.0037071.g005
Figure 6. Expression of the transgene in targeted cells. (a) RT-
PCR analysis of F9expression in targeted clones. The expected product
was amplified from all analyzed homologous recombinants after long-
term culture (more than 30 passages), while no transcript was detected
in wild-type H9 cells. (b) Western blot of the clone’s lysate using an
antibody anti human F9 protein. (c) ELISA analysis of supernatants from
recombinant culture. No F9 secretion was detected from wild-type H9
cells. The targeted clones secreted the protein at different levels.
doi:10.1371/journal.pone.0037071.g006
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trap strategy. This means that the neo gene could only be
expressed under a transcribed Pol I promoter. As a result, the
clones cannot be selected unless the transgene is targeted into an
active rDNA repeat in a dynamic chromatin structure. However,
we found that all the five selected clones expressed the Pol II gene.
This differs from the results of a previous study conducted in yeast.
The question raised by our results is whether the mechanism of the
Pol II gene silencing at the rDNA locus is similar in all eukaryotes,
from yeast to human cells. Restructuring of the rDNA clusters has
been observed among somatic cells [20]. This raises concerns
about the potential instability of any inserted transgene in the
rDNA locus and the risk that the transgene might be translocated
among the rDNA clusters or lost during mitotic expansion.
However, the odds of this happening to one specific targeted copy
out of the hundreds of rDNA copies in the human genome are
very low. They are rendered even lower by the fact that the
restructuring of the rDNA clusters during mitosis is rare.
In summary, using the strategy described here, we integrated
human coagulation factor IX into the rDNA locus of hESCs via
homologous recombination. Compared to other sites reported, this
locus proved to be subject to efficient targeting. The targeting of
hESCs at the rDNA locus did not change the main ES
characteristics of the cells and the transgene was expressed stably
in targeted hESCs. This is the first gene targeting of a human
physiological gene at a defined locus on hESCs. Our findings
indicate that the rDNA locus may serve as an ideal harbor for
transgenes in hESCs.
Materials and Methods
Cell Culture
Human fibrosarcoma cells (HT1080) were purchased from
ATCC and cultured in high-glucose Dulbecco’s modified Eagle’s
medium (4.5 g/l) supplemented with 10% fetal bovine ser-
um,2 mM L-glutamine, 0.1 mM non-essential amino acids, 50
unit/ml penicillin, and 50 mg/ml streptomycin at 37uCi na
humidified 5% CO2atmosphere. H9 cells (WiCell Research
Institute, Madison, WI, U.S.) were maintained on mitomycin-C
treated mouse embryonic fibroblasts in hESC medium containing
DMEM/F12 supplemented with 20% knockout serum replace-
ment, 2 mM L-glutamine, 1% non-essential amino acids, 0.1 mM
b-mercaptoethanol, 100 unit/ml penicillin and 100 mg/ml
streptomycin and 10 ng/ml basic fibroblast growth factor.All
components were purchased from Invitrogen. Cells were passaged
every five days mechanically or through dispase (1 mg/ml,
Invitrogen, Carlsbad, CA, U.S.) digestion.
Construction of Plasmid and Gene Targeting
Human 45S pre-RNA genes are arranged as tandem repeat
clusters on the satellite stalks (p12) of the five pairs of acrocentric
chromosomes (Chromosome 13, 14, 15, 21 and 22). All the
primers were designed according to the human ribosomal DNA
complete repeating unit (GenBank accession number U13369).
Homologous sequences were amplified from normal human
genomic DNA with the following primers:59-TTC AAT TGC
GGT GTG GGG TTC GAG GCG GTT TGA GTG AGA CG-
39/59-CCA AGT AGG AGA GGA GCG AGC GAC CAA AGG
AAC CAT AAC TG-39;59-GGG GCT CGC CGC GCT CTA
CCT TAC CTA CCT G-39/59-GCC GAT CCG AGG GCC
TCA CTA AAC CAT CCA A-39;5 9-CTG AAA CTT AAA GGA
ATT GAC GGA AGG GCA CCA CCA GGA GTG-39/59-GGG
TTG CCT CAG GCC GGC CAG ACG AGA CA-39.The Factor
IX open reading frame and the 39untranslated region were
generated using PNS-FIX as templates with the following primers:
59-GGC GTC TCA CAT GCA GCG CGT GAA CAT GAT -
39/59- CCG CTA GCT ACC CCC TAG AGC CCC AGC-
39.These introduced a Bsmb I site into the product. Neo open
reading frame, 39untranslated region and SV40 Poly A sequence
were generated using pCDNA3.1 as a template with primers 59-
GGC GTC TCA CAT GAT TGA ACA AGA-39/59-CCA TGG
CTA GCT CTA GAC GGT CGA CCC GTG CGG AAT GCT
TCC GGC TCG TAT GTT GTG T-39 which introduced human
rRNA gene terminator and recognition sites for NcoI, XbaI, and
NheI.EIF4G-IRES was amplified from human normal genomic
DNA using primers 59-GAA TTC TCT AGA TGG GGG TCC
TGG GC-39/59-TCC TCC TTG GTT GGG ATC TCG-39 as
reported [32]. All the PCR above were performed using Pyrobest
TM DNA Polymerase (Takara, Dalian, China).
For gene targeting, one passage prior to transfection, hESCs
were detached by 1 mg/ml dispase and replated on dishes coated
with Matrigel
TM (BD Biosciences, San Jose, CA, U.S.) for three
days in MEF conditioned hESC medium. Two hours before
transfection, 10 mM Y27632 was added to the medium. For
targeting, the hESCs were incubated at 37uC with trypLE
TM
Select (Invitrogen, Carlsbad, CA, U.S.) for 3 minutes. Then the
cells were immediately collected and counted. The centrifuged
cells were resuspended with 100 mL Human Stem Cell Nucleo-
fector Kit 2 (Lonza, Basel, Switzerland) and 5 mg linearized
pHrnF9 and nucleofected using Nucleofector II (Lonza, Basel,
Switzerland) using program A023. After recovery in 500 mL
RPMI-1640 (Hyclone, Beijing, China) for 5 minutes at room
temperature, the transfected cells were plated on PMEF-NL
(Millipore, Bedford, MA, U.S.) in hESC medium containing
10 mM Y27632 (Sigma, St Louis, MO, U.S.). G418 selection was
initiated 48–72 hours after transfection, depending on the cell
density. The final concentration of G418 was 50 mg/ml. About
two weeks after transfection, a portion of resistant clones was
picked and the remaining clones were fixed and stained with
Giemsa stain. Clones with diameters of $2 mm were considered
resistant.
PCR and RT-PCR
Genomic DNA was isolated from the cells using phenol/
chloroform extraction. The primers used are as follows: P1 59-
GGG TGG GGC AGG ACA GCA AGG GGG AGG AT -39;P 2
59- GGC GAT TGA TCG GCA AGC GAC GCT CAG ACA G
-39.
Total RNA was extracted using Trizol reagent (Sigma, St Louis,
MO, U.S.) and reverse transcribed using Promega’s transcription
system according to the manufacturers’ instructions. RT-PCR for
F9 was performed using primers 59- ATG CAG CGC GTG AAC
ATG A-39 and 59- TAC CTC TTT GGC CGA TTC AGA -39.
Southern Blotting
After digested with pvuII restriction enzyme (New England
Biolabs, Ipswich, MA, U.S.) overnight, 5 mg genomic DNA were
electrophoresed on a 0.8% agarose gel over night then transferred
to positively charged nylon membranes (Roche Diagnostics,
Indianapolis, IN, U.S.). l DNA Hind III (Takara, Dalian, China)
was used as molecular weight marker. The blots were hybridized
with DIG-dUTP labeled probes overnight at 42uC. After
incubation with AP-conjugated DIG-Antibody (Roche Diagnos-
tics, Indianapolis, IN, U.S.) and appropriate washing, the signals
were detected using CDP-Star (Roche Diagnostics, Indianapolis,
IN, U.S.) as a substrate for chemiluminescence. Probes were
generated by PCR DIG Probe Synthesis Kit (Roche Diagnostics,
Indianapolis, IN, U.S.) using the primers: 59 probe 59- CCC GGA
Targeting of hF9 at the rDNA Locus of hESCs
PLoS ONE | www.plosone.org 6 May 2012 | Volume 7 | Issue 5 | e37071AAC CTG GCC CTG TCT T-39 and 59-TGG GGT ACC TTC
TGG GCA TCC TTC-39;3 9 probe 59-GCT CCA TGC CCT
AAA GAG AA -39and 59-TCC ATC AAC ATA CTG CTT
CCA-39.
Karyotyping
Three-day old cell clumps were treated with 0.08 mg/ml
colcemid (Sigma, St Louis, MO, U.S.) for 2.5 hours. Then the
cells were tripsinized, centrifuged, and incubated in 0.075 M KCl
for 30 minutes at 37uC. After fixing with Carnoy fixative,
metaphase chromosome spreads were prepared using air drying.
Alkaline Phosphatase Staining and Immunofluorescence
Three day old cell clumps were fixed with 4% paraformalde-
hyde. After washing in TBST, alkaline phosphatase was stained
with 0.375 mg/ml nitrobluetetrazolium chloride and 0.188 mg/
ml 5-bromo-4-chloro-3-indolyl-phosphate (Roche, Indianapolis,
IN, U.S.), pH 9.5, for 15 minutes in darkness for detection of
alkaline phosphatase. For immunofluorescent staining, cells on
gelatin-coated coverslips were fixed in 4% paraformaldehyde and
permeabilized with 0.1% Triton-X 100. After blocking with 10%
normal donkey serum (Jackson ImmunoResearch, West Grove,
PA, U.S.), the cells were incubated with the first antibody against
Oct4 (1:200, Millipore, Bedford, MA, U.S.), SSEA-1 (1:100,
Millipore,Bedford, MA, U.S.), SSEA-3 (1:100, Millipore, Bedford,
MA, U.S.), SSEA-4 (1;200, Millipore,Bedford, MA), Tra-1-60
(1:100, Millipore, Bedford, MA, U.S.), Tra-1-81 (1:100, Millipore,
Bedford, MA, U.S.), SMA (1;200, Millipore, Bedford, MA, U.S.),
AFP (1:100, Millipore, Bedford, MA, U.S.), Tuj1 (1:300, Sigma, St
Louis, MO, U.S.), c Tn I (1:100, Millipore, Bedford, MA, U.S.),
and Mlc-2a (1:200, Synapric Systems, Goettingen, Germany) at
room temperature for 1 hour. The samples were incubated with
appropriate secondary antibodies after triple washing. DNA was
visualized using DAPI (Sigma, St Louis, MO, U.S.).
In vitro Differentiation
Three day old cell clumps were incubated with 1 mg/ml dispase
for 10 minutes at 37uC then washed with DMEM/F12. After culture
on ultra-low attachment plates for 7 days in hESC medium without
bFGF, EBs were transferred to gelatin-coated coverslips and cultured
for another 7days. Differentiated cells were analyzed by immunoflu-
orescence. Directed differentiation was performed according to the
protocol of the National Stem Cell Bank of America (https://www.
wicell.org/index.php?option=com_docman&task=doc_download
&gid=1064).
Teratomaformation and Analysis
Targeted cells from one 10 cm dish were dissociated with
0.05% trypsin/EDTA (Invitrogen) and collected in DMEM/F12.
After being washed with DMEM/F12, cells were resuspended in
140 mL DMEM/F12 and 70 mL Matrigel
TM (BD Bioscience, San
Jose, CA, U.S.). The suspension was injected subcutaneously into
the hind legs of immunocompromised mice. Eight to twelve weeks
later, the formed teratomas were removed and fixed in 4%
paraformaldehyde overnight. The fixed tissues were sectioned and
stained with hematoxylin and eosin. All procedures regarding the
care and use of animals are in accordance with institutional
guidelines. This study was approved by the Ethics Committee of
State Key Laboratory of Medical Genetics of China, No. 2008-
ANIMAL-004.
Western Blot
Protein samples were electrophoresed and electrotransferred
onto PVDF membranes (Millipore, Bedford, MA, U.S.). Blots
were incubated with a primary antibody anti-human Factor IX
(Affinity Biologicals, Canada) overnight at 4uC. The blots were
than incubated with horseradish peroxidase-conjugated secondary
antibodies(Sigma, St Louis, MO, U.S.) for 1 hour at room
temperature and detected with an ECL system (Amersham
Biosciences, Piscataway, NJ, U.S.). Prestained molecular weight
standards (Fermentas, Glen Burnie, MA, U.S.) were used to
estimate the apparent molecular weight.
ELISA
After culturing in hESC medium for three days, 24-hour-old
supernatants were collected from six-well plates. Total cells
(together with MEFs) and MEFs from parallel wells (subtracting
the number of MEFs from the total number of cells) were
trypsinized and counted. All supernatants were collected in
triplicate. ELISA was performed using Paired Antibodies for
ELISA-Factor IX (Cedarlane Laboratories, Ltd., Burlington,
Canada) according to the manufacturer’s instructions. Reference
curves were constructed using serial dilutions of normal pooled
plasma (Pacific Hemostasis, Cape Town, South Africa), with
correlation coefficient (R
2) of at least 0.990 using a 5-parameter
logistic curve fit algorithm.
Supporting Information
Figure S1 Western blot analysis of the concentrated supernatant
from targeted hES clones.
(TIF)
Table S1 Summary of the 2 experiments of gene targeting in
HT1080 cells.
(DOC)
Table S2 FIX levels in cultured supernatant from targeted
HT1080 clones.
(DOC)
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